Inhibition of irritating side effects associated with use of...

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C554S214000, C554S117000, C514S530000, C514S772400, C424S488000

Reexamination Certificate

active

06933289

ABSTRACT:
This invention relates to a method of reducing an irritating or adverse side effect associated with the topical use of an active ophthalmic drug comprising incorporating an effective amount of a cyclodextrin or cyclodextrin derivative into a formulation to complex the active drug such that the concentration of the free active drug is reduced below a tolerable threshold, and incorporating an effective amount of a viscosity increasing agent in said formulation such that the bioavailability of said drug is high enough to be therapeutically effective, wherein the cyclodextrin or cyclodextrin derivative is not required to solubilize the active drug.Another aspect of this invention relates to topical ophthalmic formulations comprising an active drug, a cyclodextrin or cyclodextrin derivative, and a viscosity-enhancing agent, in effective amounts as stated above.

REFERENCES:
patent: 4470965 (1984-09-01), Wolf et al.
patent: 4727064 (1988-02-01), Pitha
patent: 5419898 (1995-05-01), Ikejiri et al.
patent: 5422116 (1995-06-01), Yen et al.
patent: 5472954 (1995-12-01), Loftsson
patent: 5494901 (1996-02-01), Javitt et al.
patent: 5558876 (1996-09-01), Desai et al.
patent: 5688819 (1997-11-01), Woodward et al.
patent: 5891913 (1999-04-01), Sallmann et al.
patent: 6107343 (2000-08-01), Sallmann et al.
patent: 6232343 (2001-05-01), Ikari et al.
patent: 6407079 (2002-06-01), Muller et al.
patent: 6420407 (2002-07-01), Horn
patent: 6455547 (2002-09-01), Kis
patent: 6468548 (2002-10-01), Kis
patent: 6479556 (2002-11-01), Doi et al.
patent: 6562873 (2003-05-01), Olejnik et al.
patent: 6646001 (2003-11-01), Hellberg et al.
patent: 6828356 (2004-12-01), Su et al.
patent: 2002/0035264 (2002-03-01), Kararli et al.
patent: 2003/0232089 (2003-12-01), Singh et al.
patent: 0435682 (1990-12-01), None
patent: 0435682 (1990-12-01), None
patent: 0579435 (1993-07-01), None
patent: WO 94/12217 (1994-06-01), None
patent: WO 95/00144 (1995-01-01), None
Martin et al., Physical Pharmacy: Physical and Chemical Principles in the Pharmaceutical Sciences., 1993., Lea & Febiger., Fourth Edition., pp. 259-260.
U.S. Pharmacopeia., 2004 USP Dictionary of USAN and International Drug Names., pp. 119-120.
Gennaro et al.., Remington: The Science and Practice of Pharmacy., 1995., Lippincott Williams & Wilkins., Nineteenth Edition., pp. 173-178.
Bito, L.Z.Biological Protection with Prostaglandins, Cohen, M.M., ed., Boca Raton, FL, CRC Press Inc., 1985, pp 231-252.
Bito, L.Z.,Applied Pharmacology in the Medical Treatment of Glaucomas, Drance, S.M. and Neufeld, A.H., eds., New York, Grune & Stratton, 1984, pp 477-505.
Bowen, John M. et al.,Identification of Cocaine and Phencyclidine by Solute-Induced Circular Dichroism; Analytical Chemistry, vol. 53, No. 14, Dec. 1981, pp 2239-2242.
Han, Soon M. et al., Solute-Induced Circular Dichroism: Complexation of Achiral Drugs with Cyclodextrin; Analytical Chemistry, vol. 56, No. 14, Dec. 1984, pp 2822-2825.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Inhibition of irritating side effects associated with use of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of irritating side effects associated with use of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of irritating side effects associated with use of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3451351

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.